Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by Noteableon Nov 27, 2023 11:11am
134 Views
Post# 35754401

RE:RE:RE:AstraZeneca's ADC disappoints - on severe adverse events

RE:RE:RE:AstraZeneca's ADC disappoints - on severe adverse eventsNovember 27, 2023 - Experts caution that there are challenges with ADCs that still need to be overcome, including toxicities and the tumor microenvironment itself.

Nathan Tumey, associate professor at the School of Pharmacy and Pharmaceutical Sciences at Binghamton University,
 said there are still a lot of questions about what drives ADC toxicity. Previously, it was believed that the main driver was premature payload release, but he said this is no longer considered the main or only issue.

“Even very, very stable ADCs have toxicity problems,” Tumey said. “Developing an understanding of the molecular basis for ADC toxicity would be a major step forward.”


Senior biotech analyst at Piper Sandler & Co. Joe Catanzaro added that another challenge is the limited number of tumor-specific antigens in solid tumors. Due to thheterogeneity of solid tumors, ADCs have limited tumor targets that can be effected, like in advanced or metasttic breast cancer. (mBC) which is significantly hetergeneous, for example, and prone to tumor escape/ cancer treatment relapse.

https://www.biospace.com/article/next-generation-adcs-aim-to-overcome-toxicities-payload-problems-/

<< Previous
Bullboard Posts
Next >>